Predictive value of pulmonary to systemic vascular resistance ratio in systemic lupus erythematosus patients with pulmonary arterial hypertension
Authors:
Open Access
- 20 March 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 43 (6) , 1042-1048
Abstract
Objective: Pulmonary arterial hypertension (PAH) is a serious complication of systemic lupus erythematosus (SLE) with high mortality. The ratio of pulmonary to systemic vascular resistance (SVR) (Rp : Rs) may increase with disease progression. However, the prognostic value of Rp : Rs in predicting the outcomes of patients with SLE-PAH remains to be elucidated. Methods: Between 1 February 2012, and 30 June 2022, consecutive patients with a diagnosis of SLE-PAH and minimum one follow-up were enrolled prospectively. The end points were all-cause mortality and lung transplantation. The predictive values of baseline clinical characteristics and hemodynamic parameters, including Rp : Rs, were analyzed using Cox proportional hazard analyses. C-statistics were used to compare the predictive ability between the models. Results: A total of 285 patients were included and followed up for a median duration of 3.41 (interquartile range 1.81–5.72), during which 58 (20.4%) patients reached the endpoint. Multivariable Cox regression analysis revealed that in addition to the 6-minute walk distance (6MWD), the Rp : Rs was an independent predictor of the endpoint [hazard ratio 24.72; 95% confidence interval (CI) 5.59–109.29, P < 0.001] in predicting the endpoint. The concordance index for a model incorporating the Rp : Rs and the 6MWD yielded a value of 0.75 (95% CI 0.68–0.82), which showed better predictive accuracy than the simplified risk stratification strategy. Introducing the Rp : Rs ratio to the 2022 ESC/ERS four-stratum model significantly improved its predictive performance for these patients. Conclusion: The Rp : Rs serves as an independent predictor of adverse prognosis in patients with SLE-PAH and could provide additional value over current risk-assessment tools.Keywords
This publication has 29 references indexed in Scilit:
- Association Study Identified HLA‐DQA1 as a Novel Genetic Risk of Systemic Lupus Erythematosus‐Associated Pulmonary Arterial HypertensionArthritis & Rheumatology, 2023
- Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseasesAutoimmunity Reviews, 2021
- Impact of Severe Pulmonary Arterial Hypertension on the Left Heart and Prognostic ImplicationsJournal of the American Society of Echocardiography, 2019
- Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysisAutoimmunity Reviews, 2016
- Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamicsThe Journal of Heart and Lung Transplantation, 2013
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart diseaseThe American Journal of Cardiology, 1996
- Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosusSeminars in Arthritis and Rheumatism, 1984
- Pulmonary Hypertension and Congenital Heart DiseaseThe Annals of Thoracic Surgery, 1973